Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 20/20 | 0.77 |
| ▸ | VEGFA | P15692 | 5/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | ARNT | P27540 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17671103 | 1.00 | EPAS1 (0.77) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18036724 | 0.91 | EPAS1 (0.81) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL17671115 | 0.91 | EPAS1 (0.81) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL18036976 | 0.91 | EPAS1 (0.81) | EPAS1VEGFACYP2C9ARNTCYP2C19 | |
| SCHEMBL17671086 | 0.87 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL22908835 | 0.87 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL16560917 | 0.87 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL16561002 | 0.87 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL16561006 | 0.86 | EPAS1 (1.00) | EPAS1VEGFA | |
| SCHEMBL18036774 | 0.84 | EPAS1 (0.75) | EPAS1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| EP-3417851-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3417852-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-3043784-B9 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3043784-B1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | PELOTON THERAPEUTICS, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180155279-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2018-05-24 | — | — | US | disclosed |
| US-9969689-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9908845-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9896418-B2 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | PELOTON THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20170304300-A1 | HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155279-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885CYP2C9 1939/4885 |
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 47/4885CYP2C9 4715/4885 |
| US-20170304300-A1 | HIF-2alpha INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS | HIF1AN, HIF1A, EGLN2 | EPAS1 13/4885VEGFA 47/4885CYP2C9 3430/4885 |
| US-20180042884-A1 | COMPOSITIONS FOR USE IN TREATING GLIOBLASTOMA | MGMT, NEFM, TUBB3 | EPAS1 2505/4885VEGFA 189/4885CYP2C9 4881/4885 |
| US-10786480-B2 | Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | EPAS1 16/4885VEGFA 45/4885CYP2C9 4763/4885 |
| US-20160251307-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885CYP2C9 1939/4885 |
| US-10278942-B2 | Compositions for use in treating pulmonary arterial hypertension | MYLK, TNNI3, PDE2A | EPAS1 450/4885VEGFA 34/4885CYP2C9 3822/4885 |
| US-20170217892-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885CYP2C9 1939/4885 |
| US-20180140569-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 89/4885CYP2C9 4578/4885 |
| US-20170217891-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885CYP2C9 1939/4885 |
| US-20200190031-A1 | ARYL ETHERS AND USES THEREOF | HIF1AN, EGLN2, VHL | EPAS1 9/4885VEGFA 21/4885CYP2C9 1939/4885 |
| US-10335388-B2 | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof | HIF1AN, HIF1A, EGLN2 | EPAS1 15/4885VEGFA 89/4885CYP2C9 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.